Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

OTHER × Clonal Evolution × Lymphoid × Clear all

Status

Sponsor Class

Study Type

Observational 1

Sponsor

Cancer Type

Conditions

Waldenstrom Macroglobulinemia 1 Neoplasm, Residual 1

Interventions

Cyclophosphamide 791 Rituximab 782 Etoposide 340 Vincristine 339 Doxorubicin 309 fludarabine 304 Cytarabine 301 fludarabine phosphate 279 Methotrexate 271 Prednisone 253 Dexamethasone 250 Lenalidomide 223 Filgrastim 203 Melphalan 179 Radiotherapy 160 Peripheral Blood Stem Cell Transplantation 158 Whole-Body Irradiation 152 Busulfan 146 Bendamustine Hydrochloride 144 venetoclax 142 Mycophenolic Acid 141 ibrutinib 132 Granulocyte Colony-Stimulating Factor 127 Bortezomib 121 Tacrolimus 119 obinutuzumab 109 Gemcitabine 105 Cyclosporine 98 Antilymphocyte Serum 89 Carmustine 87

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT03521596 2025-11-18

FIL_BIOWM

Fondazione Italiana Linfomi - ETS

Waldenstrom Macroglobulinemia, Neoplasm, Residual

Data powered by HemOnc (CC BY 4.0) Colophon ⚡